YBX1 and non-small cell lung carcinoma: Among the 100 NSCLC patient samples, high YBX1 expression was observed in 48% of patient samples, and high LC3I/II expression was observed in 43% of the patient samples; both YBX1 and LC3I/II were statistically associated with the clinical TNM stage.